Trial Profile
Beta 3 agonist treatment in heart failure (BEAT-HF II)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms BEAT-HF
- 01 Nov 2022 According to a CVRx media release, the company expects to be able to share data from this study during the first half of 2023.
- 03 Oct 2016 New trial record